The β4 nicotinic receptor subunit modulates the chronic antidepressant effect mediated by bupropion

Neuroscience Letters

Volumn 555, Issue , 2013, Pages 68-72

  Radhakrishnan, Rajan ^a   Santamaría, Abel ^b   Escobar, Liliana ^c   Arias, Hugo Rubén ^c  

^a ROSEMAN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^c PLLC   (United States)

Author keywords

Antidepressant; Bupropion; Depression; Knockout mice; Nicotinic receptors

Indexed keywords

AMFEBUTAMONE; NICOTINIC RECEPTOR; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; FORCED SWIMMING TEST; LONG TERM CARE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT WITHDRAWAL;

ANTIDEPRESSANT; BUPROPION; DEPRESSION; KNOCKOUT MICE; NICOTINIC RECEPTORS;

ANIMALS; ANTIDEPRESSIVE AGENTS; BUPROPION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALE; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; RECEPTORS, NICOTINIC; SEX FACTORS; TIME FACTORS;

EID: 84885446290     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.08.009     Document Type: Article

References (37)

1. Arias H.R. Is the inhibition of nicotinic acetylcholine receptors by bupropion involved in its clinical actions?. Int. J. Biochem. Cell Biol. 2009, 41:2098-2108.
2. Arias H.R. Molecular interaction of bupropion with nicotine acetylcholine receptors. J. Pediatr. Biochem. 2010, 1:185-197.
3. Arias H.R., Feuerbach D., Bhumireddy P., Ortells M.O. Inhibitory mechanisms and binding site locations for serotonin selective reuptake inhibitors on nicotinic acetylcholine receptors. Int. J. Biochem. Cell Biol. 2010, 42:712-724.
4. Arias H.R., Gumilar F., Rosenberg A., Targowska-Duda K.M., Feuerbach D., Jozwiak K., Moaddel R., Weiner I.W., Bouzat C. Interaction of bupropion with muscle-type nicotinic acetylcholine receptors in different conformational states. Biochemistry 2009, 48:4506-4518.
5. Arias H.R., Rosenberg A., Targowska-Duda K.M., Feuerbach D., Jozwiak K., Moaddel R., Weiner I.W. Tricyclic antidepressants and mecamylamine bind to different sites in the human α4β2 nicotinic receptor ion channel. Int. J. Biochem. Cell Biol. 2010, 42:1007-1018.
6. Arias H.R., Santamaría A., Ali S., Pharmacological Neurotoxicological actions mediated by bupropion and diethylpropion. Int. Rev. Neurobiol. 2009, 88:223-255.
7. Arias H.R., Targowska-Duda K.M., Sullivan C.J., Feuerbach D., Maciejewski R., Jozwiak K. Different interaction between tricyclic antidepressants and mecamylamine with the human α3β4 nicotinic acetylcholine receptor. Int. Neurochem. 2010, 56:642-649.
8. Ascher J.A., Cole J.O., Colin J.N., Feighner J.P., Ferris R.M., Fibiger H.C., Golden R.N., Martin P., Potter W.Z., Richelson E., Sulser F. Bupropion: a review of its mechanism of antidepressant activity. J. Clin. Psychiatry 1995, 56:395-401.
9. Carroll F.I., Blough B.E., Mascarella S.W., Navarro H.A., Eaton J.B., Lukas R.J., Damaj M.I. Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J. Med. Chem. 2010, 53:2204-2214.
10. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci. 2002, 23:238-245.
11. Dalla C., Pitychoutis P.M., Kokras N., Papadopoulou-Daifoti Z. Sex differences in animal models of depression and antidepressant response. Basic Clin. Pharmacol. Toxicol. 2010, 106:226-233.
12. Damaj M.I., Carroll F.I., Eaton J.B., Navarro H.A., Blough B.E., Mirza S., Lukas R.J., Martin B.R. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol. Pharmacol. 2004, 66:675-682.
13. De Biasi M., Salas R. Influence of neuronal nicotinic receptors over nicotine addiction and withdrawal. Exp. Biol. Med. (Maywood) 2008, 233:917-929.
14. Dhir A., Kulkarni S.K. Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor. Eur. J. Pharmacol. 2007, 568:177-185.
15. Drago J., McColl C.D., Horne M.K., Finkelstein D.I., Ross S.A. Neuronal nicotinic receptors: insights gained from gene knockout and knockin mutant mice. Cell. Mol. Life Sci. 2003, 60:1267-1280.
16. Gonzales D., Bjornson W., Durcan M.J., White J.D., Johnston J.A., Buist A.S., Sachs D.P., Rigotti N.A., Niaura R., Hays J.T., Hurt R.D. Effects of gender on relapse prevention in smokers treated with bupropion SR. Am. J. Prev. Med. 2002, 22:234-239.
17. Gotti C., Zoli M., Clementi F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol. Sci. 2006, 27:482-491.
18. Grady S.R., Moretti M., Zoli M., Marks M.J., Zanardi A., Pucci L., Clementi F., Gotti C. Rodent habenulo-interpeduncular pathway expresses a large variety of uncommon nAChR subtypes, but only the α3β4* and α3β3β4* subtypes mediate acetylcholine release. J. Neurosci. 2009, 29:2272-2282.
19. Guyon T., Wakkach A., Poea S., Mouly V., Klingel-Schmitt I., Levasseur P., Beeson D., Asher O., Tzartos S., Berrih-Aknin S. Regulation of acetylcholine receptor gene expression in human myasthenia gravis muscles. Evidences for a compensatory mechanism triggered by receptor loss. J. Clin. Invest. 1998, 102:249-263.
20. Hedeker D., Gibbons R.D. Longitudinal data analysis. Wiley Series in Probability and Statistics 2006, Wiley-Interscience, New York. first ed.
21. Hsyu P.H., Singh A., Giargiari T.D., Dunn J.A., Ascher J.A., Johnston J.A. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J. Clin. Pharmacol. 1997, 37:737-743.
22. Katzman M.A. Current considerations in the treatment of generalized anxiety disorder. CNS Drugs. 2009, 23:103-120.
23. Kedmi M., Beaudet A.L., Orr-Urtreger A. Mice lacking neuronal nicotinic acetylcholine receptor β4-subunit and mice lacking both α5- and β4-subunits are highly resistant to nicotine-induced seizures. Physiol. Genomics 2004, 17:221-229.
24. Kornstein S.G., Schatzberg A.F., Thase M.E., Yonkers K.A., McCullough J.P., Keitner G.I., Gelenberg A.J., Davis S.M., Harrison W.M., Keller M.B. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am. J. Psychiatry 2000, 150:1445-1452.
25. Nishikawa T., Fage D., Scatton B. Evidence for, and nature of, the tonic inhibitory influence of habenulointerpeduncular pathways upon cerebral dopaminergic transmission in the rat. Brain Res. 1986, 373:324-336.
26. Rothschild R., Quitkin F.M. Review of the use of pattern analysis to differentiate true drug and placebo responses. Psychother Psychosom. 1992, 58:170-177.
27. Salas R., Pieri F., De Biasi M. Decreased signs of nicotine withdrawal in mice null for the β4 nicotinic acetylcholine receptor subunit. J. Neurosci. 2004, 24:10035-10039.
28. Salas R., Cook K.D., Bassetto L., De Biasi M. The α3 and β4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice. Neuropharmacology 2004, 47:401-407.
29. Salas R., Sturm R., Boulter J., De Biasi M. Nicotinic receptors in the habenulo-interpeduncular system are necessary for nicotine withdrawal in mice. J. Neurosci. 2009, 29:3014-3018.
30. Santamaría A., Arias H.R. Neurochemical and behavioral effects elicited by bupropion and diethylpropion in rats. Behav. Brain Res. 2010, 211:132-139.
31. Schmitz J.M., Stotts A.L., Mooney M.E., Delaune K.A., Moeller G.F. Bupropion and cognitive-behavioral therapy for smoking cessation in women. Nicotine Tob. Res. 2007, 9:699-709.
32. Semba J., Wakuta M. Chronic effect of nicotine on serotonin transporter mRNA in the raphe nucleus of rats: reversal by co-administration of bupropion. Psychiatry Clin. Neurosci. 2008, 62:435-441.
33. Seber G.A.F. Multivariate observations. Wiley Series in Probability and Statistics 2004, Wiley-Interscience, New York. second ed.
34. Shytle R.D., Silver A.A., Lukas R.J., Newman M.B., Sheehan D.V., Sanberg P.R. Nicotinic acetylcholine receptors as targets for antidepressants. Mol. Psychiatry 2002, 7:525-535.
35. Sidhpura N., Redfern P., Rowley H., Heal D., Wonnacott S. Comparison of the effects of bupropion and nicotine on locomotor activation and dopamine release in vivo. Biochem. Pharmacol. 2007, 74:1292-1298.
36. Stewart J.J., Berkel H.J., Parish R.C., Simar M.R., Syed A., Bocchini J.A., Wilson J.T., Manno J.E. Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender. J. Clin. Pharmacol. 2001, 41:770-778.
37. Papakostas G.I., Kornstein S.G., Clayton A.H., Soares C.N., Hallett L.A., Krishen A., Tucker V.L. Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender-age interactions. Int. Clin. Psychopharmacol. 2007, 22:226-229.